• EnsiliTech, a Bristol-based deeptech startup, has developed a platform based on over ten years of research in silica.
• The company’s patent-protected technology facilitates easier storage of medicines and vaccines, enhancing global access to treatment.
• The technology, known as Ensilication, forms a protective silica layer around each molecule, preventing degradation and maintaining stability without refrigeration.

About EnsiliTech

EnsiliTech is a biotechnology startup based in Bristol, established to enhance the stability of medicines and vaccines without the requirement for refrigeration. The company’s patented Ensilication technology encases molecules in a silica shell, preserving their integrity.

Founded in 2022 by Dr. Asel Sartbaeva, EnsiliTech aims to address the challenges associated with the cold chain in healthcare, which involves maintaining medicines at low temperatures during storage and transport.

Unique Features of EnsiliTech

EnsiliTech’s mission is to improve access to essential medicines globally, irrespective of geographical and healthcare system constraints. The Ensilication technology plays a central role in this mission by providing a cost-effective method to stabilize medicines and vaccines without refrigeration.

The company is led by Dr. Asel Sartbaeva and comprises a diverse team committed to fostering sustainable healthcare solutions.

Market Potential for Ensilication Technology

The current biopharmaceutical industry relies heavily on a costly and energy-intensive cold chain system. Failures within this system lead to significant financial losses and hinder access to vital treatments, particularly in developing regions.

EnsiliTech’s Ensilication technology offers a sustainable alternative, capable of maintaining stability at temperatures up to 50°C without refrigeration. This innovation has garnered significant recognition and investment, including awards and funding from Innovate UK to support the development of sustainable antibody production and new vaccines.

Technical Overview of Ensilication Technology

EnsiliTech’s platform, protected by multiple patents, applies a silica coating to biomolecules, preserving them through various production processes. This approach eliminates the need for cold-chain reliance, simplifying global distribution and improving product shelf life.

The company plans to license this technology to biopharmaceutical firms, enabling the production of heat-stable medicines and reducing dependence on cold storage infrastructure.

Further Information

For more details about EnsiliTech, visit their website at www.ensilitech.com.